{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:53:42Z","timestamp":1794635622259,"version":"4.9.1"},"reference-count":246,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.neurot.2024.e00427","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T07:32:36Z","timestamp":1722583956000},"page":"e00427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Stem cell therapeutics and gene therapy for neurologic disorders"],"prefix":"10.1016","volume":"21","author":[{"given":"Kevin S.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily J.","family":"Koubek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey A.","family":"Sakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva L.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1574888X16666210810103838","article-title":"Exploring the role of stem cell therapy in treating neurodegenerative diseases: challenges and current perspectives","volume":"17","author":"Puranik","year":"2022","journal-title":"Curr Stem Cell Res Ther"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/biology11010147","article-title":"Stem cell transplantation therapy and neurological disorders: current status and future perspectives","volume":"11","author":"Rahman","year":"2022","journal-title":"Biology"},{"key":"10.1016\/j.neurot.2024.e00427_bib3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.neuroscience.2022.03.010","article-title":"Gene therapy for neurological disease: state of the art and opportunities for next-generation approaches","volume":"490","author":"Morris","year":"2022","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00109-021-02167-y","article-title":"Advances in gene therapy for neurogenetic diseases: a brief review","volume":"100","author":"Xie","year":"2022","journal-title":"J\u00a0Mol Med (Berl)"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib5","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s41392-022-01134-4","article-title":"Stem cell-based therapy for human diseases","volume":"7","author":"Hoang","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s13287-022-02942-9","article-title":"Periodontal ligament stem cells as a promising therapeutic target for neural damage","volume":"13","author":"Mohebichamkhorami","year":"2022","journal-title":"Stem Cell Res Ther"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00427_bib7","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.stemcr.2023.06.007","article-title":"A\u00a0defined roadmap of radial glia and astrocyte differentiation from human pluripotent stem cells","volume":"18","author":"Jovanovic","year":"2023","journal-title":"Stem Cell Rep"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10571-022-01199-3","article-title":"Stem cells and tissue engineering-based therapeutic interventions: promising strategies to improve peripheral nerve regeneration","volume":"43","author":"de Assis","year":"2023","journal-title":"Cell Mol Neurobiol"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00427_bib9","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.7150\/thno.84133","article-title":"Recent advances in endogenous neural stem\/progenitor cell manipulation for spinal cord injury repair","volume":"13","author":"Li","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.neurot.2024.e00427_bib10","series-title":"Molecular and cellular therapies for motor neuron diseases","first-page":"207","article-title":"Stem cell therapy for amyotrophic lateral sclerosis","author":"Chen","year":"2017"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1385\/SCR:1:2:151","article-title":"Human embryonic stem cells: potential tool for achieving immunotolerance?","volume":"1","author":"Menendez","year":"2005","journal-title":"Stem Cell Rev"},{"issue":"15","key":"10.1016\/j.neurot.2024.e00427_bib12","doi-asserted-by":"crossref","first-page":"9864","DOI":"10.1073\/pnas.142298299","article-title":"Characterization of the expression of MHC proteins in human embryonic stem cells","volume":"99","author":"Drukker","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00427_bib13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrc3034","article-title":"The tumorigenicity of human embryonic and induced pluripotent stem cells","volume":"11","author":"Ben-David","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00401-008-0465-0","article-title":"A\u00a0patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions","volume":"117","author":"Keene","year":"2009","journal-title":"Acta Neuropathol"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib15","first-page":"101","article-title":"Embryonic stem cell research: a decade of debate from Bush to Obama","volume":"82","author":"Murugan","year":"2009","journal-title":"Yale J Biol Med"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ana.22487","article-title":"Stem cell technology for neurodegenerative diseases","volume":"70","author":"Lunn","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00427_bib17","article-title":"Mesenchymal stem cells as promoters, enhancers, and playmakers of the translational regenerative medicine 2018","volume":"2018","author":"Ballini","year":"2018","journal-title":"Stem Cell Int"},{"key":"10.1016\/j.neurot.2024.e00427_bib18","doi-asserted-by":"crossref","DOI":"10.1007\/s00429-023-02717-9","article-title":"Adult neurogenesis and \u201cimmature\u201d neurons in mammals: an evolutionary trade-off in plasticity?","author":"Bonfanti","year":"2023","journal-title":"Brain Struct Funct"},{"key":"10.1016\/j.neurot.2024.e00427_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104868","article-title":"Regulatory T cells promote remyelination in the murine experimental autoimmune encephalomyelitis model of multiple sclerosis following human neural stem cell transplant","volume":"140","author":"McIntyre","year":"2020","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2024.e00427_bib20","series-title":"Human neural stem cells restore spatial memory in a transgenic Alzheimer's disease mouse model by an immunomodulating mechanism","author":"Chen","year":"2023"},{"key":"10.1016\/j.neurot.2024.e00427_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2017.07.005","article-title":"Combined intranasal nerve growth factor and ventricle neural stem cell grafts prolong survival and improve disease outcome in amyotrophic lateral sclerosis transgenic mice","volume":"656","author":"Zhong","year":"2017","journal-title":"Neurosci Lett"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00427_bib22","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/16060","article-title":"Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient","volume":"2","author":"Piccini","year":"1999","journal-title":"Nat Neurosci"},{"issue":"22","key":"10.1016\/j.neurot.2024.e00427_bib23","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1056\/NEJM199211263272202","article-title":"Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease","volume":"327","author":"Freed","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib24","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archneur.1989.00520420033021","article-title":"Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up","volume":"46","author":"Lindvall","year":"1989","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41583-019-0257-7","article-title":"The future of stem cell therapies for Parkinson disease","volume":"21","author":"Parmar","year":"2020","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.10720","article-title":"A\u00a0double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease","volume":"54","author":"Olanow","year":"2003","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00427_bib27","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200103083441002","article-title":"Transplantation of embryonic dopamine neurons for severe Parkinson's disease","volume":"344","author":"Freed","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib28","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s41591-019-0507-2","article-title":"Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease","volume":"25","author":"Barker","year":"2019","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00427_bib29","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.stem.2023.08.014","article-title":"Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson's disease","volume":"30","author":"Kirkeby","year":"2023","journal-title":"STEM-PD. Cell Stem Cell"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00427_bib30","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1038\/nprot.2017.078","article-title":"Generation of high-purity human ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation","volume":"12","author":"Nolbrant","year":"2017","journal-title":"Nat Protoc"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.stem.2021.01.004","article-title":"Preclinical efficacy and safety of a human embryonic stem cell-derived midbrain dopamine progenitor product, MSK-DA01","volume":"28","author":"Piao","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00427_bib32","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.stem.2023.11.001","article-title":"Phase I clinical trial of intracerebroventricular transplantation of allogeneic neural stem cells in people with progressive multiple sclerosis","volume":"30","author":"Leone","year":"2023","journal-title":"Cell Stem Cell"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00427_bib33","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1212\/WNL.0000000000002889","article-title":"Transplantation of spinal cord-derived neural stem cells for ALS: analysis of phase 1 and 2 trials","volume":"87","author":"Glass","year":"2016","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib34","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/acn3.567","article-title":"Long-term Phase 1\/2 intraspinal stem cell transplantation outcomes in ALS","volume":"5","author":"Goutman","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2024.e00427_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12967-014-0371-2","article-title":"Human neural stem cell transplantation in ALS: initial results from a phase I trial","volume":"13","author":"Mazzini","year":"2015","journal-title":"J\u00a0Transl Med"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib36","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1073\/pnas.95.7.3996","article-title":"A\u00a0tripotential glial precursor cell is present in the developing spinal cord","volume":"95","author":"Rao","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib37","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1523\/JNEUROSCI.12-07-02751.1992","article-title":"Astrocyte precursors in neonatal rat spinal cord cultures","volume":"12","author":"Fok-Seang","year":"1992","journal-title":"J\u00a0Neurosci"},{"issue":"6053","key":"10.1016\/j.neurot.2024.e00427_bib38","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/319499a0","article-title":"Proliferating bipotential glial progenitor cells in adult rat optic nerve","volume":"319","author":"Ffrench-Constant","year":"1986","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib39","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1179\/1743132810Y.0000000024","article-title":"In vitro culture and characterization of oligodendrocyte precursor cells derived from neonatal rats","volume":"33","author":"Wu","year":"2011","journal-title":"Neurol Res"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib40","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/jnr.10397","article-title":"Progenitor cells derived from the adult human subcortical white matter disperse and differentiate as oligodendrocytes within demyelinated lesions of the rat brain","volume":"69","author":"Windrem","year":"2002","journal-title":"J\u00a0Neurosci Res"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00427_bib41","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/jnr.21646","article-title":"Adult human spinal cord harbors neural precursor cells that generate neurons and glial cells in vitro","volume":"86","author":"Dromard","year":"2008","journal-title":"J\u00a0Neurosci Res"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib42","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41583-020-0314-2","article-title":"Transplanting neural progenitor cells to restore connectivity after spinal cord injury","volume":"21","author":"Fischer","year":"2020","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00427_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201900285","article-title":"Cortical transplantation of brain-mimetic glycosaminoglycan scaffolds and neural progenitor cells promotes vascular regeneration and functional recovery after ischemic stroke in mice","volume":"9","author":"McCrary","year":"2020","journal-title":"Adv Healthcare Mater"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00427_bib44","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.4103\/1673-5374.355820","article-title":"Neural progenitor cells derived from fibroblasts induced by small molecule compounds under hypoxia for treatment of Parkinson's disease in rats","volume":"18","author":"Guo","year":"2023","journal-title":"Neural Regen Res"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00427_bib45","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.stem.2023.08.013","article-title":"Human pallial MGE-type GABAergic interneuron cell therapy for chronic focal epilepsy","volume":"30","author":"Bershteyn","year":"2023","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib46","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/0963689718820271","article-title":"Transplantation of human neural progenitor cells (NPC) into putamina of parkinsonian patients: a case series study, safety and efficacy four years after surgery","volume":"28","author":"Madrazo","year":"2019","journal-title":"Cell Transplant"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00427_bib47","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.1007\/s12035-021-02574-9","article-title":"Gliotoxicity and glioprotection: the dual role of glial cells","volume":"58","author":"Quincozes-Santos","year":"2021","journal-title":"Mol Neurobiol"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib48","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/glia.23922","article-title":"Glial restricted precursor cells in central nervous system disorders: current applications and future perspectives","volume":"69","author":"Martins-Macedo","year":"2021","journal-title":"Glia"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib49","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12967-023-03903-3","article-title":"Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx(R)) in ALS patients: phase I\/IIa clinical trial results","volume":"21","author":"Gotkine","year":"2023","journal-title":"J\u00a0Transl Med"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib50","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/glia.21119","article-title":"Human glial-restricted progenitors survive, proliferate, and preserve electrophysiological function in rats with focal inflammatory spinal cord demyelination","volume":"59","author":"Walczak","year":"2011","journal-title":"Glia"},{"issue":"6106","key":"10.1016\/j.neurot.2024.e00427_bib51","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1126\/science.1218071","article-title":"Glial progenitor cell-based treatment and modeling of neurological disease","volume":"338","author":"Goldman","year":"2012","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202002944","article-title":"Mesenchymal stem cells for neurological disorders","volume":"8","author":"Andrzejewska","year":"2021","journal-title":"Adv Sci"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213032","article-title":"Comparative study of the neural differentiation capacity of mesenchymal stromal cells from different tissue sources: an approach for their use in neural regeneration therapies","volume":"14","author":"Urrutia","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib54","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3350\/cmh.2020.0194","article-title":"The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future","volume":"27","author":"Watanabe","year":"2021","journal-title":"Clin Mol Hepatol"},{"issue":"11","key":"10.1016\/j.neurot.2024.e00427_bib55","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1089\/scd.2011.0430","article-title":"beta-PIX is critical for transplanted mesenchymal stromal cell migration","volume":"21","author":"Koh","year":"2012","journal-title":"Stem Cell Dev"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib56","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1089\/scd.2009.0453","article-title":"Bone marrow-derived stromal cells from amyotrophic lateral sclerosis patients have diminished stem cell capacity","volume":"19","author":"Cho","year":"2010","journal-title":"Stem Cell Dev"},{"issue":"Pt 11","key":"10.1016\/j.neurot.2024.e00427_bib57","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1093\/brain\/awh273","article-title":"Wild-type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues","volume":"127","author":"Corti","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2024.e00427_bib58","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.brainres.2009.08.012","article-title":"Intra-bone marrow-bone marrow transplantation slows disease progression and prolongs survival in G93A mutant SOD1 transgenic mice, an animal model mouse for amyotrophic lateral sclerosis","volume":"1296","author":"Ohnishi","year":"2009","journal-title":"Brain Res"},{"issue":"11","key":"10.1016\/j.neurot.2024.e00427_bib59","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/nen.0b013e318158822b","article-title":"Adult olfactory bulb neural precursor cell grafts provide temporary protection from motor neuron degeneration, improve motor function, and extend survival in amyotrophic lateral sclerosis mice","volume":"66","author":"Martin","year":"2007","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib60","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s13287-022-03050-4","article-title":"The potential use of mesenchymal stem cells and their exosomes in Parkinson's disease treatment","volume":"13","author":"Heris","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.neurot.2024.e00427_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.1011225","article-title":"Mesenchymal stromal cells for the treatment of Alzheimer's disease: strategies and limitations","volume":"15","author":"Regmi","year":"2022","journal-title":"Front Mol Neurosci"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib62","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/jnr.23368","article-title":"Stem cell factor-activated bone marrow ameliorates amyotrophic lateral sclerosis by promoting protective microglial migration","volume":"92","author":"Terashima","year":"2014","journal-title":"J\u00a0Neurosci Res"},{"issue":"19","key":"10.1016\/j.neurot.2024.e00427_bib63","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1093\/hmg\/ddq293","article-title":"Systemic transplantation of c-kit+ cells exerts a therapeutic effect in a model of amyotrophic lateral sclerosis","volume":"19","author":"Corti","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00427_bib64","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.semcdb.2019.03.003","article-title":"Mesenchymal stem cell therapies in brain disease","volume":"95","author":"Sherman","year":"2019","journal-title":"Semin Cell Dev Biol"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib65","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1177\/0271678X16665853","article-title":"Real-time MRI for precise and predictable intra-arterial stem cell delivery to the central nervous system","volume":"37","author":"Walczak","year":"2017","journal-title":"J\u00a0Cerebr Blood Flow Metabol"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib66","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/stem.1118","article-title":"Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation","volume":"30","author":"von Bahr","year":"2012","journal-title":"Stem Cell"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib67","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1200\/JCO.2000.18.2.307","article-title":"Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy","volume":"18","author":"Koc","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00427_bib68","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1161\/STROKEAHA.109.575993","article-title":"Biodistribution of neural stem cells after intravascular therapy for hypoxic-ischemia","volume":"41","author":"Pendharkar","year":"2010","journal-title":"Stroke"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00427_bib69","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jcyt.2015.04.007","article-title":"Early neuroprotective effect with lack of long-term cell replacement effect on experimental stroke after intra-arterial transplantation of adipose-derived mesenchymal stromal cells","volume":"17","author":"Oh","year":"2015","journal-title":"Cytotherapy"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib70","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/stem.430","article-title":"A\u00a0long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke","volume":"28","author":"Lee","year":"2010","journal-title":"Stem Cell"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib71","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41576-019-0100-z","article-title":"Induced pluripotent stem cells in disease modelling and drug discovery","volume":"20","author":"Rowe","year":"2019","journal-title":"Nat Rev Genet"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00427_bib72","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib73","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/stem.2570","article-title":"Concise review: induced pluripotent stem cell research in the era of precision medicine","volume":"35","author":"Hamazaki","year":"2017","journal-title":"Stem Cell"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00427_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2019.03.004","article-title":"Using induced pluripotent stem cell neuronal models to study neurodegenerative diseases","volume":"1866","author":"Zhang","year":"2020","journal-title":"Biochim Biophys Acta, Mol Basis Dis"},{"key":"10.1016\/j.neurot.2024.e00427_bib75","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ebiom.2019.11.026","article-title":"Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity","volume":"50","author":"Birger","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neurot.2024.e00427_bib76","article-title":"Human iPSC for therapeutic approaches to the nervous system: present and future applications","volume":"2016","author":"Cefalo","year":"2016","journal-title":"Stem Cell Int"},{"issue":"20","key":"10.1016\/j.neurot.2024.e00427_bib77","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1915872","article-title":"Personalized iPSC-derived dopamine progenitor cells for Parkinson's disease","volume":"382","author":"Schweitzer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00427_bib78","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.reth.2020.06.002","article-title":"iPS cell-based therapy for Parkinson's disease: a Kyoto trial","volume":"13","author":"Takahashi","year":"2020","journal-title":"Regen Ther"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib79","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13287-021-02274-0","article-title":"Advances in intranasal application of stem cells in the treatment of central nervous system diseases","volume":"12","author":"Zhang","year":"2021","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00427_bib80","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12975-016-0482-6","article-title":"Stem cell therapy and administration routes after stroke","volume":"7","author":"Rodriguez-Frutos","year":"2016","journal-title":"Transl Stroke Res"},{"key":"10.1016\/j.neurot.2024.e00427_bib81","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.neuroscience.2010.11.054","article-title":"Functional recovery after hematic administration of allogenic mesenchymal stem cells in acute ischemic stroke in rats","volume":"175","author":"Gutierrez-Fernandez","year":"2011","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib82","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.transproceed.2006.12.019","article-title":"Stem cell transplantation: the lung barrier","volume":"39","author":"Schrepfer","year":"2007","journal-title":"Transplant Proc"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00427_bib83","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3727\/096368916X690971","article-title":"Breaking the blood-brain barrier with mannitol to aid stem cell therapeutics in the chronic stroke brain","volume":"25","author":"Tajiri","year":"2016","journal-title":"Cell Transplant"},{"issue":"14","key":"10.1016\/j.neurot.2024.e00427_bib84","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1039\/D3BM00376K","article-title":"Cellular modifications and biomaterial design to improve mesenchymal stem cell transplantation","volume":"11","author":"Wong","year":"2023","journal-title":"Biomater Sci"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00427_bib85","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1213\/01.ane.0000258021.03211.d0","article-title":"Intravenous mononuclear marrow cells reverse neuropathic pain from experimental mononeuropathy","volume":"104","author":"Klass","year":"2007","journal-title":"Anesth Analg"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00427_bib86","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archneurol.2010.248","article-title":"Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis","volume":"67","author":"Karussis","year":"2010","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib87","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4103\/1673-5374.243723","article-title":"Safety of intrathecal injection of Wharton's jelly-derived mesenchymal stem cells in amyotrophic lateral sclerosis therapy","volume":"14","author":"Barczewska","year":"2019","journal-title":"Neural Regen Res"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00427_bib88","doi-asserted-by":"crossref","first-page":"693","DOI":"10.52586\/4980","article-title":"A\u00a0phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis","volume":"26","author":"Petrou","year":"2021","journal-title":"Front Biosci"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib89","doi-asserted-by":"crossref","first-page":"590","DOI":"10.5966\/sctm.2014-0212","article-title":"Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis","volume":"4","author":"Oh","year":"2015","journal-title":"Stem Cells Transl Med"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib90","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/mus.27472","article-title":"A\u00a0randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis","volume":"65","author":"Cudkowicz","year":"2022","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib91","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/08820139.2018.1504301","article-title":"Therapeutic use of intrathecal mesenchymal stem cells in patients with multiple sclerosis: a pilot study with booster injection","volume":"48","author":"Sahraian","year":"2019","journal-title":"Immunol Invest"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib92","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1179\/2045772315Y.0000000048","article-title":"Intrathecal transplantation of autologous adipose-derived mesenchymal stem cells for treating spinal cord injury: a human trial","volume":"39","author":"Hur","year":"2016","journal-title":"J\u00a0Spinal Cord Med."},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib93","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1038\/s41467-024-46259-y","article-title":"Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: phase I trial","volume":"15","author":"Bydon","year":"2024","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00427_bib94","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.4103\/1673-5374.332151","article-title":"Dose optimization of intrathecal administration of human umbilical cord mesenchymal stem cells for the treatment of subacute incomplete spinal cord injury","volume":"17","author":"Cao","year":"2022","journal-title":"Neural Regen Res"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib95","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1212\/WNL.0000000000007720","article-title":"Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy","volume":"93","author":"Singer","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib96","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13287-024-03748-7","article-title":"The safety profile of mesenchymal stem cell therapy administered through intrathecal injections for treating neurological disorders: a systematic review and meta-analysis of randomised controlled trials","volume":"15","author":"Mesa","year":"2024","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib97","first-page":"261","article-title":"Stem cell transplantation into the intraventricular space via an Ommaya reservoir in a patient with amyotrophic lateral sclerosis","volume":"56","author":"Baek","year":"2012","journal-title":"J\u00a0Neurosurg Sci"},{"issue":"Pt 1","key":"10.1016\/j.neurot.2024.e00427_bib98","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1042\/BA20030173","article-title":"Stem-cell plasticity and therapy for injuries of the peripheral nervous system","volume":"40","author":"Tohill","year":"2004","journal-title":"Biotechnol Appl Biochem"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib99","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.trci.2015.06.007","article-title":"Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase 1 clinical trial","volume":"1","author":"Kim","year":"2015","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib100","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1227\/NEU.0000000000000156","article-title":"Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I trial, cervical microinjection, and final surgical safety outcomes","volume":"74","author":"Riley","year":"2014","journal-title":"Neurosurgery"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib101","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ana.24113","article-title":"Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes","volume":"75","author":"Feldman","year":"2014","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib102","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.yexmp.2015.01.016","article-title":"Intranasal delivery of stem cells as therapy for central nervous system disease","volume":"98","author":"Li","year":"2015","journal-title":"Exp Mol Pathol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib103","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jamaneurol.2017.3129","article-title":"A\u00a0review of the current therapies, challenges, and future directions of transcranial focused ultrasound technology: advances in diagnosis and treatment","volume":"75","author":"Krishna","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2024.e00427_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.749047","article-title":"Focused ultrasound mediated opening of the blood-brain barrier for neurodegenerative diseases","volume":"12","author":"Fishman","year":"2021","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib105","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/WNP.0000000000000488","article-title":"Therapeutic potentials of localized blood-brain barrier disruption by noninvasive transcranial focused ultrasound: a technical review","volume":"37","author":"Cammalleri","year":"2020","journal-title":"J\u00a0Clin Neurophysiol"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib106","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1148\/radiol.2202001804","article-title":"Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits","volume":"220","author":"Hynynen","year":"2001","journal-title":"Radiology"},{"key":"10.1016\/j.neurot.2024.e00427_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.669449","article-title":"MRI guided focused ultrasound-mediated delivery of therapeutic cells to the brain: a review of the state-of-the-art methodology and future applications","volume":"12","author":"Ahmed","year":"2021","journal-title":"Front Neurol"},{"issue":"11","key":"10.1016\/j.neurot.2024.e00427_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027877","article-title":"Targeted delivery of neural stem cells to the brain using MRI-guided focused ultrasound to disrupt the blood-brain barrier","volume":"6","author":"Burgess","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib109","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1177\/0963689717715824","article-title":"Magnetic enhancement of stem cell-targeted delivery into the brain following MR-guided focused ultrasound for opening the blood-brain barrier","volume":"26","author":"Shen","year":"2017","journal-title":"Cell Transplant"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib110","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/1061186X.2019.1656724","article-title":"Low intensity ultrasound targeted microbubble destruction assists MSCs delivery and improves neural function in brain ischaemic rats","volume":"28","author":"Cui","year":"2020","journal-title":"J\u00a0Drug Target"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065712","article-title":"Endogenous neural stem cell activation after low-intensity focused ultrasound-induced blood-brain barrier modulation","volume":"24","author":"Seo","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib112","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1371\/journal.pone.0000166","article-title":"Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington's disease","volume":"2","author":"Krystkowiak","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2024.e00427_bib113","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/164_2021_544","article-title":"Immune suppression in allogeneic hematopoietic stem cell transplantation","volume":"272","author":"Michniacki","year":"2022","journal-title":"Handb Exp Pharmacol"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00427_bib114","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1046","article-title":"Monoclonal antibody-mediated immunosuppression enables long-term survival of transplanted human neural stem cells in mouse brain","volume":"12","author":"McGinley","year":"2022","journal-title":"Clin Transl Med"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib115","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/14712598.2011.566852","article-title":"The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation","volume":"11","author":"Busca","year":"2011","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.neurot.2024.e00427_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105842","article-title":"Stem cell therapy for central nervous system disorders: metabolic interactions between transplanted cells and local microenvironments","volume":"173","author":"Sakowski","year":"2022","journal-title":"Neurobiol Dis"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib117","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ana.24584","article-title":"Intraspinal stem cell transplantation for amyotrophic lateral sclerosis","volume":"79","author":"Chen","year":"2016","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib118","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/13543784.2019.1627324","article-title":"Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials","volume":"28","author":"Goutman","year":"2019","journal-title":"Expet Opin Invest Drugs"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00427_bib119","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.stem.2022.04.002","article-title":"Biomaterials to enhance stem cell transplantation","volume":"29","author":"Kharbikar","year":"2022","journal-title":"Cell Stem Cell"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00427_bib120","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd.2018.158","article-title":"Gene therapy for neurological disorders: progress and prospects","volume":"17","author":"Deverman","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib121","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s13311-018-00694-0","article-title":"Gene therapy for neurodegenerative diseases","volume":"16","author":"Sudhakar","year":"2019","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib122","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1517\/14712598.2016.1114096","article-title":"Gene therapy for neurological disorders","volume":"16","author":"Choong","year":"2016","journal-title":"Expet Opin Biol Ther"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib123","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.neurot.2024.e00427_bib124","series-title":"Atlas of neuromuscular diseases","first-page":"35","article-title":"New neuromuscular therapies","author":"Savelieff","year":"2021"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00427_bib125","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrneurol.2013.56","article-title":"Progress in gene therapy for neurological disorders","volume":"9","author":"Simonato","year":"2013","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00427_bib126","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"issue":"14","key":"10.1016\/j.neurot.2024.e00427_bib127","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","article-title":"Delandistrogene moxeparvovec: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00427_bib128","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","article-title":"AAV-based in vivo gene therapy for neurological disorders","volume":"22","author":"Ling","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib129","first-page":"15","article-title":"Gene therapy for huntington's disease: the final strategy for a cure?","volume":"15","author":"Byun","year":"2022","journal-title":"J\u00a0Mov Disord"},{"key":"10.1016\/j.neurot.2024.e00427_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112075","article-title":"Gene therapy in epilepsy","volume":"143","author":"Zhang","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00427_bib131","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.molmed.2015.06.001","article-title":"Gene therapy for neurodegenerative diseases","volume":"21","author":"O'Connor","year":"2015","journal-title":"Trends Mol Med"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib132","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2018.0233","article-title":"Adeno-associated viral vector (serotype 2)-nerve growth factor for patients with alzheimer disease: a randomized clinical trial","volume":"75","author":"Rafii","year":"2018","journal-title":"JAMA Neurol"},{"issue":"7-8","key":"10.1016\/j.neurot.2024.e00427_bib133","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/hum.2019.367","article-title":"Postmortem analysis in a clinical trial of AAV2-NGF gene therapy for alzheimer's disease identifies a need for improved vector delivery","volume":"31","author":"Castle","year":"2020","journal-title":"Hum Gene Ther"},{"issue":"9579","key":"10.1016\/j.neurot.2024.e00427_bib134","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","article-title":"Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial","volume":"369","author":"Kaplitt","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00427_bib135","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","article-title":"AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial","volume":"10","author":"LeWitt","year":"2011","journal-title":"Lancet Neurol"},{"issue":"21","key":"10.1016\/j.neurot.2024.e00427_bib136","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","article-title":"Results from a phase I safety trial of hAADC gene therapy for Parkinson disease","volume":"70","author":"Eberling","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00427_bib137","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/hum.2011.220","article-title":"Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease","volume":"23","author":"Mittermeyer","year":"2012","journal-title":"Hum Gene Ther"},{"issue":"20","key":"10.1016\/j.neurot.2024.e00427_bib138","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","article-title":"Safety and tolerability of putaminal AADC gene therapy for Parkinson disease","volume":"73","author":"Christine","year":"2009","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib139","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1212\/WNL.0000000000012952","article-title":"Safety of AADC gene therapy for moderately advanced Parkinson disease: three-year outcomes from the PD-1101 trial","volume":"98","author":"Christine","year":"2022","journal-title":"Neurology"},{"issue":"9923","key":"10.1016\/j.neurot.2024.e00427_bib140","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","article-title":"Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1\/2 trial","volume":"383","author":"Palfi","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00427_bib141","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","article-title":"Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial","volume":"7","author":"Marks","year":"2008","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib142","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ana.24436","article-title":"Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial","volume":"78","author":"Warren","year":"2015","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00427_bib143","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2024.e00427_bib144","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1146\/annurev-pharmtox-010919-023738","article-title":"Antisense drugs make sense for neurological diseases","volume":"61","author":"Bennett","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00427_bib145","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/gt.2017.34","article-title":"How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy","volume":"24","author":"Singh","year":"2017","journal-title":"Gene Ther"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib146","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5863\/1551-6776-24.3.194","article-title":"Nusinersen: a novel antisense oligonucleotide for the treatment of spinal muscular atrophy","volume":"24","author":"Neil","year":"2019","journal-title":"J\u00a0Pediatr Pharmacol Therapeut"},{"key":"10.1016\/j.neurot.2024.e00427_bib147","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2147\/DDDT.S162913","article-title":"Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis","volume":"13","author":"Mathew","year":"2019","journal-title":"Drug Des Dev Ther"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib148","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: first approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.neurot.2024.e00427_bib149","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-1-0716-2772-3_2","article-title":"Viltolarsen: from preclinical studies to FDA approval","volume":"2587","author":"Roshmi","year":"2023","journal-title":"Methods Mol Biol"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib150","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: first approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00427_bib151","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","article-title":"Exploratory tau biomarker results from a multiple ascending-dose study of BIIB080 in alzheimer disease: a randomized clinical trial","volume":"80","author":"Edwards","year":"2023","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib152","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00427_bib153","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nbt1216-1213","article-title":"Alnylam terminates revusiran program, stock plunges","volume":"34","author":"Garber","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"23","key":"10.1016\/j.neurot.2024.e00427_bib154","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMc2300400","article-title":"Tominersen in adults with manifest huntington's disease","volume":"389","author":"McColgan","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00427_bib155","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00427_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2022.101148","article-title":"RNA interference (RNAi)-based therapeutics for treatment of rare neurologic diseases","volume":"91","author":"Germain","year":"2023","journal-title":"Mol Aspect Med"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib157","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41591-019-0674-1","article-title":"Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS","volume":"26","author":"Bravo-Hernandez","year":"2020","journal-title":"Nat Med"},{"issue":"46","key":"10.1016\/j.neurot.2024.e00427_bib158","doi-asserted-by":"crossref","first-page":"53177","DOI":"10.1021\/acsami.3c08756","article-title":"Enhanced nose-to-brain delivery of combined small interfering RNAs using lesion-recognizing nanoparticles for the synergistic therapy of alzheimer's disease","volume":"15","author":"Li","year":"2023","journal-title":"ACS Appl Mater Interfaces"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00427_bib159","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nn1531","article-title":"Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model","volume":"8","author":"Singer","year":"2005","journal-title":"Nat Neurosci"},{"issue":"16","key":"10.1016\/j.neurot.2024.e00427_bib160","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10360","key":"10.1016\/j.neurot.2024.e00427_bib161","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","article-title":"Amyotrophic lateral sclerosis","volume":"400","author":"Feldman","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib162","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 suppression with adeno-associated virus and MicroRNA in familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00427_bib163","series-title":"Patisiran","author":"Kalola","year":"2024"},{"issue":"15","key":"10.1016\/j.neurot.2024.e00427_bib164","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s40265-023-01943-z","article-title":"Vutrisiran: a review in polyneuropathy of hereditary transthyretin-mediated amyloidosis","volume":"83","author":"Nie","year":"2023","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib165","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/sctm.19-0338","article-title":"Genome-edited adult stem cells: next-generation advanced therapy medicinal products","volume":"9","author":"Benabdellah","year":"2020","journal-title":"Stem Cells Transl Med"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib166","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/mt.2016.10","article-title":"Genome-editing technologies for gene and cell therapy","volume":"24","author":"Maeder","year":"2016","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00427_bib167","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ymthe.2019.01.014","article-title":"Genome editing with mRNA encoding ZFN, TALEN, and Cas9","volume":"27","author":"Zhang","year":"2019","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib168","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nbt796","article-title":"Human zinc fingers as building blocks in the construction of artificial transcription factors","volume":"21","author":"Bae","year":"2003","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib169","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nbt0202-135","article-title":"Engineering polydactyl zinc-finger transcription factors","volume":"20","author":"Beerli","year":"2002","journal-title":"Nat Biotechnol"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib170","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1073\/pnas.96.6.2758","article-title":"Toward controlling gene expression at will: selection and design of zinc finger domains recognizing each of the 5'-GNN-3' DNA target sequences","volume":"96","author":"Segal","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5959","key":"10.1016\/j.neurot.2024.e00427_bib171","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1126\/science.1178811","article-title":"Breaking the code of DNA binding specificity of TAL-type III effectors","volume":"326","author":"Boch","year":"2009","journal-title":"Science"},{"issue":"5959","key":"10.1016\/j.neurot.2024.e00427_bib172","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.1178817","article-title":"A\u00a0simple cipher governs DNA recognition by TAL effectors","volume":"326","author":"Moscou","year":"2009","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib173","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib174","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s12035-021-02638-w","article-title":"CRISPR-Cas9-Mediated gene therapy in neurological disorders","volume":"59","author":"Guan","year":"2022","journal-title":"Mol Neurobiol"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct Targeted Ther"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00427_bib176","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe1611","article-title":"Persistent repression of tau in the brain using engineered zinc finger protein transcription factors","volume":"7","author":"Wegmann","year":"2021","journal-title":"Sci Adv"},{"issue":"45","key":"10.1016\/j.neurot.2024.e00427_bib177","doi-asserted-by":"crossref","first-page":"E3136","DOI":"10.1073\/pnas.1206506109","article-title":"Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6\/2 mice","volume":"109","author":"Garriga-Canut","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib178","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.stem.2012.04.026","article-title":"Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells","volume":"11","author":"An","year":"2012","journal-title":"Cell Stem Cell"},{"issue":"13","key":"10.1016\/j.neurot.2024.e00427_bib179","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/hmg\/ddaa106","article-title":"Correction of amyotrophic lateral sclerosis related phenotypes in induced pluripotent stem cell-derived motor neurons carrying a hexanucleotide expansion mutation in C9orf72 by CRISPR\/Cas9 genome editing using homology-directed repair","volume":"29","author":"Ababneh","year":"2020","journal-title":"Hum Mol Genet"},{"issue":"9-10","key":"10.1016\/j.neurot.2024.e00427_bib180","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/hum.2023.29241.bfs","article-title":"CRISPR therapeutics, vertex complete rolling biologics license applications for exa-cel in sickle cell disease, beta thalassemia","volume":"34","author":"Philippidis","year":"2023","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib181","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41467-023-37507-8","article-title":"Prime editing with genuine Cas9 nickases minimizes unwanted indels","volume":"14","author":"Lee","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib182","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41580-023-00697-6","article-title":"CRISPR technologies for genome, epigenome and transcriptome editing","volume":"25","author":"Villiger","year":"2024","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.neurot.2024.e00427_bib183","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3389\/fphar.2019.00724","article-title":"Gene therapy tools for brain diseases","volume":"10","author":"Ingusci","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.neurot.2024.e00427_bib184","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2016.02.013","article-title":"Viral vectors for therapy of neurologic diseases","volume":"120","author":"Choudhury","year":"2017","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00427_bib185","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1039\/D1NR06939J","article-title":"Overcoming barriers in non-viral gene delivery for neurological applications","volume":"14","author":"Tasset","year":"2022","journal-title":"Nanoscale"},{"key":"10.1016\/j.neurot.2024.e00427_bib186","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3389\/fphar.2018.00971","article-title":"Non-viral delivery of nucleic acids: insight into mechanisms of overcoming intracellular barriers","volume":"9","author":"Durymanov","year":"2018","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib187","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/gt.2014.91","article-title":"Noninvasive, neuron-specific gene therapy can be facilitated by focused ultrasound and recombinant adeno-associated virus","volume":"22","author":"Wang","year":"2015","journal-title":"Gene Ther"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib188","first-page":"989","article-title":"Safe and stable noninvasive focal gene delivery to the mammalian brain following focused ultrasound","volume":"130","author":"Stavarache","year":"2018","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.neurot.2024.e00427_bib189","article-title":"Noninvasive, targeted, and non-viral ultrasound-mediated GDNF-plasmid delivery for treatment of Parkinson's disease","volume":"6","author":"Fan","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057682","article-title":"Noninvasive and targeted gene delivery into the brain using microbubble-facilitated focused ultrasound","volume":"8","author":"Hsu","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib191","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.expneurol.2011.10.027","article-title":"Targeted gene delivery to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption","volume":"233","author":"Huang","year":"2012","journal-title":"Exp Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib192","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jconrel.2012.08.012","article-title":"Focused ultrasound for targeted delivery of siRNA and efficient knockdown of Htt expression","volume":"163","author":"Burgess","year":"2012","journal-title":"J\u00a0Contr Release"},{"issue":"11","key":"10.1016\/j.neurot.2024.e00427_bib193","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1089\/hum.2012.013","article-title":"Targeted delivery of self-complementary adeno-associated virus serotype 9 to the brain, using magnetic resonance imaging-guided focused ultrasound","volume":"23","author":"Thevenot","year":"2012","journal-title":"Hum Gene Ther"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib194","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/gt.2015.25","article-title":"Gene delivery to the spinal cord using MRI-guided focused ultrasound","volume":"22","author":"Weber-Adrian","year":"2015","journal-title":"Gene Ther"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00427_bib195","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/sj.gt.3300994","article-title":"Immune responses to adenovirus and adeno-associated virus in humans","volume":"6","author":"Chirmule","year":"1999","journal-title":"Gene Ther"},{"issue":"11","key":"10.1016\/j.neurot.2024.e00427_bib196","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/sj.gt.3302048","article-title":"Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences","volume":"10","author":"Lowenstein","year":"2003","journal-title":"Gene Ther"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00427_bib197","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","article-title":"Therapeutic AAV gene transfer to the nervous system: a clinical reality","volume":"101","author":"Hudry","year":"2019","journal-title":"Neuron"},{"issue":"21","key":"10.1016\/j.neurot.2024.e00427_bib198","doi-asserted-by":"crossref","first-page":"11288","DOI":"10.1073\/pnas.93.21.11288","article-title":"Site-specific integration by adeno-associated virus","volume":"93","author":"Linden","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib199","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1073\/pnas.87.6.2211","article-title":"Site-specific integration by adeno-associated virus","volume":"87","author":"Kotin","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00427_bib200","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/hum.2017.009","article-title":"Recombinant adeno-associated viral integration and genotoxicity: insights from animal models","volume":"28","author":"Chandler","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00427_bib201","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00427_bib202","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1089\/hum.2016.147","article-title":"AAV infection: protection from cancer","volume":"28","author":"Srivastava","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"165","key":"10.1016\/j.neurot.2024.e00427_bib203","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003454","article-title":"Long-term follow-up after gene therapy for canavan disease","volume":"4","author":"Leone","year":"2012","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.neurot.2024.e00427_bib204","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1089\/104303402760128612","article-title":"Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain","volume":"13","author":"Janson","year":"2002","journal-title":"Hum Gene Ther"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib205","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol Ther"},{"issue":"18","key":"10.1016\/j.neurot.2024.e00427_bib206","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3-4","key":"10.1016\/j.neurot.2024.e00427_bib207","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/hum.2022.163","article-title":"Biodistribution of adeno-associated virus gene therapy following cerebrospinal fluid-directed administration","volume":"34","author":"Chen","year":"2023","journal-title":"Hum Gene Ther"},{"issue":"9-10","key":"10.1016\/j.neurot.2024.e00427_bib208","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1089\/hum.2021.245","article-title":"Efficacy and safety of a Krabbe disease gene therapy","volume":"33","author":"Hordeaux","year":"2022","journal-title":"Hum Gene Ther"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib209","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib210","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/humc.2018.081","article-title":"Long-term follow-up of a phase I\/II study of ProSavin, a lentiviral vector gene therapy for Parkinson's disease","volume":"29","author":"Palfi","year":"2018","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00427_bib211","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/gt.2009.17","article-title":"A\u00a0human trial of HSV-mediated gene transfer for the treatment of chronic pain","volume":"16","author":"Wolfe","year":"2009","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00427_bib212","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40824-019-0156-z","article-title":"Recent advances in the development of gene delivery systems","volume":"23","author":"Sung","year":"2019","journal-title":"Biomater Res"},{"key":"10.1016\/j.neurot.2024.e00427_bib213","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jconrel.2020.10.068","article-title":"Single-cell transfection technologies for cell therapies and gene editing","volume":"330","author":"Duckert","year":"2021","journal-title":"J\u00a0Contr Release"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00427_bib214","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1021\/acsabm.9b01131","article-title":"From endocytosis to nonendocytosis: the emerging era of gene delivery","volume":"3","author":"Zhou","year":"2020","journal-title":"ACS Appl Bio Mater"},{"issue":"20","key":"10.1016\/j.neurot.2024.e00427_bib215","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24203744","article-title":"Biodegradable polymers for gene delivery","volume":"24","author":"Thomas","year":"2019","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00427_bib216","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1021\/acsnano.8b07858","article-title":"Lipid-based DNA therapeutics: hallmarks of non-viral gene delivery","volume":"13","author":"Buck","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.neurot.2024.e00427_bib217","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jconrel.2022.02.010","article-title":"Current state of the art in peptide-based gene delivery","volume":"343","author":"Hadianamrei","year":"2022","journal-title":"J\u00a0Contr Release"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib218","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jconrel.2008.08.014","article-title":"Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS","volume":"132","author":"Cardoso","year":"2008","journal-title":"J\u00a0Contr Release"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00427_bib219","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11060-018-2966-6","article-title":"Inhibition of glioma growth by a GOLPH3 siRNA-loaded cationic liposomes","volume":"140","author":"Yuan","year":"2018","journal-title":"J\u00a0Neuro Oncol"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219995","article-title":"PrPC knockdown by liposome-siRNA-peptide complexes (LSPCs) prolongs survival and normal behavior of prion-infected mice immunotolerant to treatment","volume":"14","author":"Bender","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2024.e00427_bib221","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.2147\/IJN.S215941","article-title":"Development and screening of brain-targeted lipid-based nanoparticles with enhanced cell penetration and gene delivery properties","volume":"14","author":"Dos Santos Rodrigues","year":"2019","journal-title":"Int J Nanomed"},{"issue":"14","key":"10.1016\/j.neurot.2024.e00427_bib222","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202100540","article-title":"Recent advances in stimulus-responsive nanocarriers for gene therapy","volume":"8","author":"Yu","year":"2021","journal-title":"Adv Sci"},{"key":"10.1016\/j.neurot.2024.e00427_bib223","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jconrel.2017.04.010","article-title":"Angiogenesis-targeting microbubbles combined with ultrasound-mediated gene therapy in brain tumors","volume":"255","author":"Chang","year":"2017","journal-title":"J\u00a0Contr Release"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib224","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1021\/acs.nanolett.7b00616","article-title":"Novel focused ultrasound gene therapy approach noninvasively restores dopaminergic neuron function in a rat Parkinson's disease model","volume":"17","author":"Mead","year":"2017","journal-title":"Nano Lett"},{"issue":"41","key":"10.1016\/j.neurot.2024.e00427_bib225","doi-asserted-by":"crossref","first-page":"38190","DOI":"10.1021\/acsami.9b15014","article-title":"Effect of PEGylated magnetic PLGA-PEI nanoparticles on primary hippocampal neurons: reduced nanoneurotoxicity and enhanced transfection efficiency with magnetofection","volume":"11","author":"Cui","year":"2019","journal-title":"ACS Appl Mater Interfaces"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib226","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s40291-021-00555-1","article-title":"Elivaldogene autotemcel: first approval","volume":"25","author":"Keam","year":"2021","journal-title":"Mol Diagn Ther"},{"issue":"17","key":"10.1016\/j.neurot.2024.e00427_bib227","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10322","key":"10.1016\/j.neurot.2024.e00427_bib228","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.neurot.2024.e00427_bib229","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa2106596","article-title":"Hematopoietic stem- and progenitor-cell gene therapy for hurler syndrome","volume":"385","author":"Gentner","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00427_bib230","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-141762","article-title":"Ex-vivo autologous stem cell gene therapy clinical trial for mucopolysaccharidosis type IIIA: trial in progress-NCT04201405","volume":"136","author":"Kinsella","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib231","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5966\/sctm.2015-0103","article-title":"Human cortical neural stem cells expressing insulin-like growth factor-I: a novel cellular therapy for alzheimer's disease","volume":"5","author":"McGinley","year":"2016","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.neurot.2024.e00427_bib232","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1306004","article-title":"Human neural stem cells restore spatial memory in a transgenic Alzheimer's disease mouse model by an immunomodulating mechanism","volume":"15","author":"Chen","year":"2023","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.neurot.2024.e00427_bib233","first-page":"281","article-title":"Microglial AGE-albumin is critical for neuronal death in Parkinson's disease: a possible implication for theranostics","author":"Bayarsaikhan","year":"2015","journal-title":"Int J Nanomed"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00427_bib234","doi-asserted-by":"crossref","first-page":"114","DOI":"10.15283\/ijsc18110","article-title":"CRISPR\/Cas9 edited sRAGE-MSCs protect neuronal death in Parkinson's disease model","volume":"12","author":"Lee","year":"2019","journal-title":"Int J Stem Cells"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00427_bib235","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm1239","article-title":"A\u00a0phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease","volume":"11","author":"Tuszynski","year":"2005","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00427_bib236","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/s41591-022-01956-3","article-title":"Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1\/2a trial","volume":"28","author":"Baloh","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib237","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nn863","article-title":"Dyskinesias following neural transplantation in Parkinson's disease","volume":"5","author":"Hagell","year":"2002","journal-title":"Nat Neurosci"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib238","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.stem.2016.03.014","article-title":"Chemical control of grafted human PSC-derived neurons in a mouse model of Parkinson's disease","volume":"18","author":"Chen","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00427_bib239","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1177\/0192623320918241","article-title":"Accept or reject: the role of immune tolerance in the development of stem cell therapies and possible future approaches","volume":"49","author":"Haworth","year":"2021","journal-title":"Toxicol Pathol"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00427_bib240","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","article-title":"Targeted disruption of HLA genes via CRISPR-cas9 generates iPSCs with enhanced immune compatibility","volume":"24","author":"Xu","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00427_bib241","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/mds.24062","article-title":"Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease","volume":"27","author":"Cubo","year":"2012","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00427_bib242","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/mus.21358","article-title":"Can we eliminate placebo in ALS clinical Trials?","volume":"39","author":"Simmons","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neurot.2024.e00427_bib243","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-3-662-44519-8_8","article-title":"Great expectations: the placebo effect in Parkinson's disease","volume":"225","author":"Lidstone","year":"2014","journal-title":"Handb Exp Pharmacol"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00427_bib244","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/mds.21894","article-title":"Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00427_bib245","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/archpsyc.61.4.412","article-title":"Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial","volume":"61","author":"McRae","year":"2004","journal-title":"Arch Gen Psychiatr"},{"issue":"45","key":"10.1016\/j.neurot.2024.e00427_bib246","doi-asserted-by":"crossref","first-page":"10390","DOI":"10.1523\/JNEUROSCI.3458-05.2005","article-title":"Neurobiological mechanisms of the placebo effect","volume":"25","author":"Benedetti","year":"2005","journal-title":"J\u00a0Neurosci"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924001132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924001132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T13:16:09Z","timestamp":1728479769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747924001132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":246,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1878747924001132"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00427","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stem cell therapeutics and gene therapy for neurologic disorders","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00427","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00427"}}